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http://www.biomedcentral.com/1471-2334/14/181RESEARCH ARTICLE Open AccessDrug resistance in HIV patients with virological
failure or slow virological response to
antiretroviral therapy in Ethiopia
Alemseged Abdissa1,2*, Daniel Yilma3, Jannik Fonager4, Anne M Audelin4, Lone H Christensen4, Mette F Olsen5,
Markos Tesfaye6, Pernille Kaestel5, Tsinuel Girma7, Abraham Aseffa8, Henrik Friis5, Court Pedersen2
and Aase B Andersen2Abstract
Background: The ongoing scale-up of antiretroviral therapy (ART) in sub-Saharan Africa has prompted the interest
in surveillance of transmitted and acquired HIV drug resistance. Resistance data on virological failure and mutations
in HIV infected populations initiating treatment in sub-Saharan Africa is sparse.
Methods: HIV viral load (VL) and resistance mutations pre-ART and after 6 months were determined in a prospective
cohort study of ART-naïve HIV patients initiating first-line therapy in Jimma, Ethiopia. VL measurements were done
at baseline and after 3 and 6 months. Genotypic HIV drug resistance (HIVDR) was performed on patients exhibiting
virological failure (>1000 copies/mL at 6 months) or slow virological response (>5000 copies/mL at 3 months
and <1000 copies/mL at 6 months).
Results: Two hundred sixty five patients had VL data available at baseline and at 6 months. Virological failure was
observed among 14 (5.3%) participants out of 265 patients. Twelve samples were genotyped and six had HIV drug
resistance (HIVDR) mutations at baseline. Among virological failures, 9/11 (81.8%) harbored one or more HIVDR
mutations at 6 months. The most frequent mutations were K103N and M184VI.
Conclusions: Our data confirm that the currently recommended first-line ART regimen is efficient in the vast majority
of individuals initiating therapy in Jimma, Ethiopia eight years after the introduction of ART. However, the documented
occurrence of transmitted resistance and accumulation of acquired HIVDR mutations among failing patients justify
increased vigilance by improving the availability and systematic use of VL testing to monitor ART response, and
underlines the need for rapid, inexpensive tests to identify the most common drug resistance mutations.Background
In Ethiopia approximately 1.3 million people live with HIV
and the estimated adult HIV prevalence is 1.5% [1]. During
the past eight years, there has been a rapid scale-up of
antiretroviral therapy (ART) which reached 250,000 adults
in 2012, representing 86% of eligible patients [2,3].
As ART roll-out continues in resource-limited settings,
the risk of potential emergence of HIV drug resistance
(HIVDR) is growing. This could be due to the absence of
virological monitoring in routine clinical care and the use* Correspondence: alemseged.abdisssa@ju.edu.et
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unless otherwise stated.of drugs with low genetic barriers such as non-nucleoside
reverse transcriptase inhibitors [NNRTI] [4]. The use of
nevirapine as monotherapy for preventing mother-to-
child transmission may have further contributed to the
problem [5].
Viral replication under suboptimal antiretroviral pressure
leads to accumulation of resistance mutations, which limit
future therapeutic choices [6] as mutations conferring
resistance to one drug frequently confer cross resistance to
other antiretroviral drugs within the same class [7]. Thus,
it is essential for patient management to define the pattern
of both primary and secondary resistance mutations.
The World Health Organization (WHO) recommends
surveillance for transmitted HIVDR among antiretroviral-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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during treatment in all countries involved in the ARV
access programs [8,9]. Although transmitted and acquired
HIV-1 drug resistance mutations have been well-described
and longitudinally surveyed in high-income countries such
as France [10], United States [11] and Denmark [12] there
are few data on the subject in resource-limited settings.
The aim of our study was to assess the prevalence of
virological failure and resistance mutations in patients
initiating treatment in Ethiopia.
Methods
Study setting
The present study was part of a randomized controlled
trial evaluating two nutritional supplements in adult
patients initiating ART in Ethiopia, which was registered
at www.controlled-trials.com (ISRCTN32453477). There
were no differences in virological suppression among
intervention groups (Olsen MF et al., submitted). The
Ethiopian ART program was initiated in 2005 free of
charge in hospitals and followed by the expansion to
health centers in the periphery in 2007. Patients initiating
ART at Jimma University Hospital, Jimma Health Center
and Agaro Health Center were enrolled between July 2010
and August 2012. The first two centers are located in
Jimma (a city of 150,000 inhabitants), with an urban site
managing a total of approximately 1,617 patients on ART
in Jimma University Hospital and 317 in Jimma Health
center. The third centre is located in Agaro (a small town
of 28,000 inhabitants) with approximately 240 patients
on treatment.
Study participants
HIV-positive patients attending the ART clinics, who were
ART naïve and eligible for ART according to the Ethiopian
national guideline [13], were invited to participate in
the study and followed for 6 months. Inclusion criteria
were being adult (≥18 years), living within approximately
50 km of Jimma, and consenting to participate. Pregnant
or lactating women and patients with known previous use
of ART were excluded. Participants gave informed consent
and protocols were approved by Jimma University Ethics
Review Board and National Research Ethics Committee
of Ethiopia.
Decision to initiate treatment was made according to
WHO criteria: stage IV irrespective of CD4 count, stage
III if CD4 < 350, or CD4 < 200 cells/μl at any stage. The
choice of ART combination was guided by national
treatment guideline [13] and generally consisted of one
of three first line regimens [Tenofovir (TDF) + Lamivudine
(3TC) +Nevirapine (NVP)/Efavirenz (EFV); or Zidovudine
(AZT) + 3TC + NVP/EFV; or Stavudine (d4T) + 3TC +
NVP/EFV]. As part of the ART program, patients collected
drugs every month for free. CD4 counts were monitored atART initiation and every 6 months. Viral load monitoring
was performed as part of this study.
Specimen collection and processing
Whole blood was obtained for CD4 count and plasma
samples were separated and stored at −80°C until ana-
lyzed for HIV viral load and genotype. CD4 count and
viral loads were measured at baseline and after 3 and 6
months on therapy. Genotypic HIVDR was done at base-
line and after 6 months among selected participants
based on viral load levels.
Viral load and CD4 count
HIV-1 viral load (VL) was quantified using a commercial
PCR assay (RealTime HIV-1, Abbott Laboratories, Illinois,
USA) and automated extraction system (m2000 Real Time
System, Abbott Laboratories, Illinois, USA) was used.
Extracted samples were amplified and detected on the
m2000rt platform (Abbott Laboratories, Illinois, USA).
Virological failure was defined as a confirmed VL >1000
copies/mL at 6 months and viral suppression is the
success of attaining VL <1000 copies/mL at 6 months.
Virological slow responders were defined as VL ≥5000
copies/mL at 3 months but with viral suppression at 6
months. CD4 cells were enumerated using the Facscount®
automated cell counter (Becton-Dickinson, Franklin Lakes,
New Jersey, USA). Immunological failure was defined
as a decline in CD4 count from baseline after 6 months
of ART [14].
Adherence to the ART
Self-reported adherence to ART was documented monthly.
In addition, efavirenz or nevirapine plasma concentrations
were measured at 1 and 2 months using liquid chromatog-
raphy-tandem mass spectrometry at Division of Clinical
Pharmacology, university of Cape Town, South Africa.
Limit of quantification was 0.01 μg/ml for both drugs.
Resistance genotyping
Plasma samples were shipped to Copenhagen, Denmark
on dry ice for drug resistance mutation analysis at Statens
Serum Institut (SSI, Copenhagen DK). Amplification of
the pol gene was performed in two steps using Super-
Script™ III One-Step RT-PCR System with Platinum® Taq
High Fidelity (Invitrogen) in accordance with manufac-
turer´s instructions. First cDNA synthesis and first PCR
was performed using the primers JA203 [15] and IN3 [16]
at the following conditions: 52°C 30 min, 94°C, 2 min
followed by 40 cycles of: 94°C, 15 sec; 60°C, 45 sec; 66°C,
3 min and a final extension at: 66°C for 10 min. The
second nested-PCR was performed using the Expand
High Fidelity PCR System (Roche) in accordance with
manufacturer´s instructions and with the primers JA204
[15] and ABI1_R [17] at the following conditions: 94°C, 2
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72°C, 60 sec, and a final extension at: 72°C for 7 min,
yielding a PCR fragment of 1449 bp. PCR products were
prepared for sequencing using IllustraTM ExoProStar 1
step (GE Healthcare) and sequencing reactions were
carried out using the BigDye Terminator version 1.1
(Applied Biosystems) and the sequencing primers:
INH-A:CTTCAGAGCAGACCAGAGCCAA,
INH-B:GTTAAACAATGGCCATTGACAGA,
INH-D:CAGRCYGGAGCCAACAGC,INH-C:GATG
GAAAGGATCACCRGCAATA, INH-F:TTGGGCCAT
CCATTCCTGG,
INH-G:CCATCCCTGTGGAAGCACAT
INH-H:TTCTGTATTTCTGCTAYTAAGTCTTTTG.
Sequencing was performed on an ABI 377 DNA Sequen-
cer (Applied Biosystems) and sequence assembly and ana-
lysis was performed in BioNumerics v. 6.6 (Applied Maths,
Sint-Martens-Latem, Belgium). For six of the 29 analyzed
samples (Id #_month; 25_6, 146_6, 301_6, 314_6, 360_6
and 25_0), sequences were obtained using the ViroSeq
HIV-1 genotyping System v. 2 (Abbott Diagnostics, Foster
City, CA) in accordance with manufacturer´s instructions.
Drug resistance mutation analysis and statistical methods
For each sequence, the resistance profile was calculated
using the current HIVdb algorithm [18] at Stanford’s HIV
genotypic resistance profile (http://sierra2.stanford.edu/
sierra/servlet/JSierra?action=sequenceInput) and as im-
plemented in BioNumerics v. 6.6.
Statistical analysis was done using STATA/IC version
11.2 (StataCorp LP, College Station, USA). Differences in
means, medians and proportions between men and women
were tested using Pearson Chi-square test and the Fisher’s
exact test. P-values <0.05 were considered significant.
Sequences submitted to GenBank
Sequences obtained in this study were submitted to
GenBank under the following accession numbers: KJ561
122-KJ561136 (baseline samples) and KJ561137-KJ5611
50 (6 months samples).
Results
Participants and their baseline characteristics
A total of 312 adult patients on first-line ART were
enrolled into the study. Of these, 281 and 273 had
reached 3 and 6 months of follow up, respectively, while
the rest dropped out for various reasons including
withdrawal of consent, lost to follow up or death. A
total of 275 participants had VL results available at 3
months and 265 at 6 months. At ART initiation, the 265
participants retained for 6 months of follow-up did not
differ significantly from the rest of participants (n =47),
in terms of baseline characteristics such as age, BMI,
VL and WHO stage. The mean (±SD) age was 33.0 (±8.8)years and 67% were women (Table 1). A combination
of tenofovir (TDF), lamuvidine (3TC) and efavirenz (EFV)
or nevirapine (NVP) was the most commonly (82.6%) pre-
scribed first-line regimen. The other first-line regimens
contained zidovudine (AZT; 14.3%) or stavudine (d4T; 3%)
instead of TDF.
Virological outcomes and immunological criteria
Virological failure was observed in 14 (5.3%) of the
participants. Three of the participants with good viral
suppression at 6 months had a slow response. These
participants (Id # 146, 301 and 314) had 184878, 6849
and 125562 copies/mL at 3 months, respectively (Table 2).
It was found that 158/275 (57.5%) and 233/265 (87.9%)
of the participants achieved VL <40 copies/mL at 3 and
6 months respectively. Patients experiencing virological
failure had significantly lower CD4 count at 6 months
mean (±SD) =169 (±85) compared to those with successful
viral suppression 313 (±131); P = 0.002). However, only
four of the 14 participants with virological failure (28.6%)
experienced immunological failure at 6 month (Table 2)
and, 22 of 251 (8.7%) participants with virological suppres-
sion experienced immunological failure.
HIVDR mutations at baseline
HIVDR genotyping was performed in pre-ART plasma
specimens from 12 participants with virological failure.
All patients were infected with HIV subtype C. Resistances
to NNRTIs were identified in six of 12 (50%) and none
were resistant to NRTI. Mutations detected in three of the
patients are associated with high level resistance. Five
participants with HIVDR mutations at ART initiation
received ART regimens that were only partially active
(Additional file 1: Table S1). During the 6 months of
follow-up, none of these patients were switched to a
fully active first-line or second-line regimen.
A total of seven patients had HIVDR mutations detect-
able in the baseline samples; one mutation (V90IV) con-
fers no resistance (Id # 339). The K103N/X was the most
common mutation observed. However, one participant
(Id # 25) had a mutation (A98G) that confers resistance to
nevirapine. This patient was treated with a supposedly
active efavirenz based regimen and the mutation had
disappeared at 6 months (Additional file 1: Table S1).
HIVDR mutations at 6 months
HIVDR genotyping was performed in plasma from 11
participants with virological failure at 6 months. Nine of
them (81.8%) harboured mutations that cause high level
resistance to NNRTIs. Six participants had the mutations at
baseline, and three (Id # 9, 339 and 346) acquired additional
mutations during follow-up causing resistance to NRTI.
Three of the participants with HIVDR had no resistance
at baseline but acquired resistance mutations during the
Table 1 Baseline characteristics of HIV-1 positive participants treated with first-line ART regiments in Jimma,
Ethiopia (n =312)
Women (n =179) Men (n =86) Total (n = 265) Excluded, did not complete 6 months (n =47)
Age, y 31.0 ±8.0 38.0 ±9.0 33.0 ±8.8 32.2
Body mass index (BMI), kg/m2 19.6 ±2.5 19.1 ±1.8 19.4 ±2.3 19.5 ±2.5
CD4 count at enrollment, cells/ul 189 ±113 194 ±113 190.7 ±113 181 ±105
Viral load, log(copies/mL ) 4.7 ±1.0 4.6 ±0.9 4.7 ±1.0 4.8 ±0.9
WHO stage
Stage I 63 (35.2) 23 (26.7) 86 (32.5) 11 (23.4)
Stage II 47 (26.3) 32 (37.2) 79 (29.8) 12 (25.5)
Stage III 53 (29.6) 26 (30.2) 79 (29.8) 19 (40.4)
Stage IV 16 (8.9) 5 (5.8 ) 21 (7.9) 5 (10.6)
ART regimen
TDF/3TC/EFV 113 (63.1) 77 (89.5) 190 (71.7) 33 (70.2)
AZT/3TC/EFV 2 (1.1) 1 (1.2) 3 (1.1) 1 (2.1)
TDF/3TC/NVP 27 (15.1) 2 (2.3) 29 (10.9) 3 (5.7)
AZT/3TC/NVP 31 (17.3) 4 (4.7) 35 (13.2) 10 (18.9)
Other* 6 (3.4) 2 (2.3) 8 (3.0) 0 (0.0)
*Other regimen includes mainly D4T and NVP based treatment. Data are mean ±SD or n (%).
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both NNRTIs and NRTIs. HIVDR genotyping could not
be performed for 3 participants (Id # 164, 354 and 373)
due to failed sequencing attempt or sample inadequacy
(Additional file 1: Table S1).
Of the three slow responders, one (Id # 301) was resist-
ant to all three drugs prescribed, while we found no evi-
dence of HIVDR in the other two participants at 6 months
(Id # 146 and 314) (Additional file 1: Table S1). The former
had pre-existing mutation and acquired additional muta-
tions developing high level resistance to all the three
antiretroviral drugs during the course of treatment
(Additional file 1: Table S1).
All cases of HIVDR involved at least one NNRTI mu-
tation, with the K103N (3/9) being the most frequently
observed. Combined NNRTI and NRTI mutations were
seen in four of nine (44.4%) participants and involved
M184V/I in all cases and K65R and D67G occurred in
one participant in addition to the M184I mutation. A
K65R mutation was also detected in a slow responding
patient. While five of 11 participants with virological
failure received ART regimens that were not or only
partially active, the other four became resistant during
the therapy in spite of a fully active ART regimens initiated
at baseline (Additional file 1: Table S1).
A total of four participants, two from the virologicaly
failing group and another two from the slow responders
had no HIVDR mutations at 6 months. Self reported
adherence data indicated that all participants with geno-
type data had good treatment adherence except two of
the slow responders (Id # 301 and 314). Measurements ofNNRTIs plasma concentrations indicated two out of nine
participants with resistance mutations at 6 months (Id #
213 and 269) and one participant with no resistance muta-
tion (Id # 357) had a drug concentration below the limit
of quantification at 1 and 2 months (Table 2).
Discussion
This report describes virological failure or slow virological
response and associated HIVDR mutations in a cohort of
HIV patients initiating first-line regimen in the Ethiopian
national ART roll out program. The study revealed a viro-
logical failure rate of 5.3% and transmitted resistance
among 6/12 of the virological failures in this cohort.
Resistance mutations were detected in 9/11 (81.8%) of
the patients failing treatment at 6 months. Although the
virological failure rate was low, the transmitted resistance
documented in this study, in a setting where ART has only
been available for eight years is alarming.
A strength of this study is that patients were closely
followed in a clinical trial unit for regular clinical and
laboratory monitoring at 3 and 6 months, leading to reli-
able identification of virological failure and minimizing
losses-to-follow-up. The potential limitation is that the
patients participated in a nutritional intervention study
in which they were motivated to come to the ART clinic
and perhaps had better ART adherence, compared to
patients accessing treatment in a regular setting. The
drug resistance mutation analysis was done only on
virological failures because of limited resource. Thus,
the actual rate of transmitted drug resistance was not
estimated.
Table 2 Characteristics of participants with virological failure and slow virological responders
Viral load (copies/mL) CD4 (cells/μl)
Patient Id Age Sex At 3 months At 6 months At baseline At 6 months Decline in CD4 count NNRTI conc, μg/ml
at 1 month
NNRTI conc, μg/ml
at 2 months
>95% reported
adherence
Virological failures
9 40 M 16816 7703 124 235 No 2.16 2.27 Yes
25 39 M 54 116373 114 163 No 4.6 4.64 Yes
157 47 M 91377 51498 41 153 No 2.9 Missing Yes
164 22 F <40 11420 127 178 No 3.88 1.39 Yes
213 35 F 767340 29427 114 251 No <0.01 <0.01 Yes
243 26 F <40 163259 207 116 Yes 8.7 8.04 Yes
269 30 F 86463 66498 207 331 No <0.01 0.01 Yes
300 50 F Undetectable 28038 119 199 No Missing 2.48 Yes
339 30 F 42735 381889 19 81 No 10.9 10.1 Yes
346 25 F Missing 2002 225 357 No 5.34 Missing Yes
354 40 M 12237 30252 137 122 Yes 2.32 2.94 Yes
357 30 F 24931 143175 221 240 No <0.01 <0.01 Yes
360 32 F 7289 111647 287 192 Yes 18.6 Missing Yes
373 34 F 344294 78504 48 5 Yes <0.01 <0.01 Yes
Slow virological responders
146 20 F 184878 141 131 360 No 4.42 6.54 Yes
301 30 F 6849 640 79 214 No 4.33 Missing No
314 50 F 125562 379 72 72 No Missing <0.01 No
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rates obtained from different studies must be interpreted
with caution, since threshold and duration of ART at time
of failure varies. In a review from Sub-Saharan Africa
countries (in which Ethiopia was not included), it was
reported that virological success (defined by a VL < 400
copies/mL) rates after 6 months of ART was 78% [19].
In fact, 67% of the patients obtained viral suppression
when applying lower cut-off values for success (VL less
than 40 or 50 copies/mL). In this study, VL <40 copies/mL
at 6 months was achieved in 87.9% of participants. Thus,
compared with data from other Sub-Saharan African
countries, the success rates found in the present study
was higher using the same threshold.
The patterns of HIVDR mutations among the patients
failing treatment in the present study differed from those
described in previous two studies conducted in Ethiopia.
In a study conducted in Gondar, only two mutations (V75I
and G190A) were detected among 92 ART-naïve patients
in 2003, before ART roll out [20]. Another investigation in
Addis Ababa did not find any mutations among 39 women
attending antenatal care units in 2005 [21]. In our study
however, several mutations, which may cause moderate to
high level of resistance to the NNRTIs and NRTIs were
detected, indicating a changing pattern and a rise in
transmitted resistance to antiretroviral drugs in Ethiopia.
Although derived from a small study, it is noticeable that
9/11 (81.8%) study participants genotyped at treatment
failure had acquired or transmitted HIVDR, which is
higher than the 63.7% reported from a study of 2000
HIV positive patients initiating first line ART using the
WHO approach in other east African countries between
2006 and 2010 [22]. In three of nine participants with
HIVDR mutations at baseline, exposure to a failing regi-
men during 6 months was associated with the emergence
of additional mutations under drug pressure, including
M184V/I. Among participants failing therapy and geno-
typed, two did not show any evidence of HIVDR muta-
tions. Both participants reported very good adherence.
However, efavirenz plasma concentrations in one of the
participants were below limit of quantification at both 1
and 2 months visits. Although, reduced absorption could
not be ruled out, the virological failure in this participant
is likely due to undisclosed poor adherence [23].
Overall, the NRTI and NNRTI transmitted and acquired
mutation patterns that were identified were consistent
with previous reports in similar settings [19,24,25]. The
most frequent NRTI mutation (M184V) and NNRTI
mutations (K103N) described in this study are known to be
common in cases of treatment failure [22]. The pres-
ence of transmitted resistance mutations has important
implications for clinical management of HIV patients
[26,27]. In addition, an immunological criterion alone
has limitations to detect virological failures as shown inthis study. These raise concerns about the routine use
of the first-line regimens without access to viral load
determination in Ethiopia.
Interestingly, one of the three patients exhibiting slow
virological response had high level resistance to all the
three drugs, although the VL was below 1000 copies/mL
at 6 months. This may be due to the K65R mutation that
can impair replicative fitness of the virus [28]. However,
one of the virological failure also carried K65R; and the
difference in virological outcome of these patients could
be due to modulation of fitness cost by mutational inter-
actions [29]. It is also interesting to note that many of
the failing patients (70%) had VL >5000 copies/mL at 3
months in contrast to those with successful viral sup-
pression, which highlights the potential of this criterion
to identify virological failure and HIVDR earlier.
Conclusions
In summary, we report virological success and resistance
rates and pattern of HIVDR mutations among Ethiopian
patients initiating first-line ART. After eight years of large-
scale ART introduction, this survey demonstrated a low
rate of virological failure. However, major mutations in-
cluding K103N and M184V were identified, indicating
that access to virological monitoring is of paramount
importance to prevent inappropriate drug switches and
preserve efficacy of ART in resource constrained countries.
Moreover, the findings underscore the need for rapid
and inexpensive tests to identify the most common
drug resistant mutations.
Additional file
Additional file 1: Table S1. Known HIV drug resistance mutations and
resistance in samples from patients with virological failure and slow
virological responders at baseline and 6 months.
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